PMID- 30848404
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1573-7322 (Electronic)
IS  - 1382-4147 (Linking)
VI  - 24
IP  - 4
DP  - 2019 Jul
TI  - Effects of European Society of Cardiology guidelines on medication profiles after 
      hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015.
PG  - 499-510
LID - 10.1007/s10741-019-09777-2 [doi]
AB  - Prescriber adherence to guideline-recommended medication in patients with heart 
      failure (HF) in clinical practice is suboptimal. We analyzed how evolving 
      guideline recommendations influenced medication profiles after a first HF 
      hospitalization. We extracted medication profiles from the Dutch PHARMO Database 
      Network for 22,476 patients with a diagnosis of HF at hospital discharge between 
      2001 and 2015. The percentage of patients prescribed the combination of a 
      beta-blocker (BB) and an angiotensin-converting-enzyme inhibitor (ACEI) or 
      angiotensin-receptor blocker (ARB) increased from 24 to approximately 45% within 
      this 15-year period. The percentage of patients who also used a 
      mineralocorticoid-receptor antagonist (MRA) reached approximately 20%. The 
      probability of being prescribed these combinations decreased with increasing age. 
      As a consequence of the policy change in the ESC guideline 2001, the use of BB 
      increased from less than 40% in 2001 to about 70% by 2015. The percentage of 
      patients prescribed an ACEI and/or an ARB, an MRA, or a diuretic was about 
      stable, at respectively 63%, 37%, and 82%. Although the 2012 ESC guideline also 
      advised MRA in the New York Heart Association (NYHA) class II, there was no 
      increase in MRA prescriptions. Compliance with the ESC guidelines varied for the 
      individual recommendations. Remarkably, there was no significant increase in MRA 
      prescriptions. At the same time, developments were demonstrated, which were not 
      instigated by the guidelines, like the shift from ACEI to ARB. Although the exact 
      HF classification of our patients was unknown, given a relatively stable case 
      mix, our data provide insight into "real-world" pharmacological management.
FAU - Kruik-Kolloffel, Willemien J
AU  - Kruik-Kolloffel WJ
AUID- ORCID: 0000-0001-6204-9027
AD  - Department of Clinical Pharmacy, Saxenburgh Group, P.O. Box 1, 7770 AA, 
      Hardenberg, the Netherlands. w.kruik@sxb.nl.
AD  - Department of Clinical Pharmacy, Hospital Group Twente, Almelo and Hengelo, the 
      Netherlands. w.kruik@sxb.nl.
FAU - Linssen, Gerard C M
AU  - Linssen GCM
AD  - Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, the 
      Netherlands.
FAU - Kruik, H Joost
AU  - Kruik HJ
AD  - Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, the 
      Netherlands.
FAU - Movig, Kris L L
AU  - Movig KLL
AD  - Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, the 
      Netherlands.
FAU - Heintjes, Edith M
AU  - Heintjes EM
AD  - PHARMO Institute, Utrecht, the Netherlands.
FAU - van der Palen, Job
AU  - van der Palen J
AD  - Medical School Twente, Medisch Spectrum Twente, Enschede, the Netherlands.
AD  - Department of Research Methodology, Measurement and Data Analysis, University of 
      Twente, Enschede, the Netherlands.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Heart Fail Rev
JT  - Heart failure reviews
JID - 9612481
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Cardiotonic Agents/*therapeutic use
MH  - Databases, Factual
MH  - Drug Prescriptions/standards/statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Drug Utilization/statistics & numerical data
MH  - Female
MH  - Guideline Adherence/statistics & numerical data
MH  - Heart Failure/*drug therapy
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Netherlands
MH  - *Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/standards/statistics & numerical data
OTO - NOTNLM
OT  - Drug therapy
OT  - Guideline adherence
OT  - Health plan implementation
OT  - Heart failure
OT  - Pharmacoepidemiology
OT  - Practice guideline
EDAT- 2019/03/09 06:00
MHDA- 2020/04/14 06:00
CRDT- 2019/03/09 06:00
PHST- 2019/03/09 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/03/09 06:00 [entrez]
AID - 10.1007/s10741-019-09777-2 [pii]
AID - 10.1007/s10741-019-09777-2 [doi]
PST - ppublish
SO  - Heart Fail Rev. 2019 Jul;24(4):499-510. doi: 10.1007/s10741-019-09777-2.